International Journal of Endocrinology / 2016 / Article / Tab 2

Research Article

Cardiometabolic Risk in Hyperlipidemic Men and Women

Table 2

Characteristics of the study sample with prediabetes, divided by sex.

(female/male)FemaleMale value

Age [years]19/290.007
Body weight19/28<0.001
BMI [kg/m2]19/280.360
Waist [cm]18/270.001
RRS [mmHg]14/200.164
RRD [mmHg]14/200.223
TC [mg/dL]19/290.371
LDL-C [mg/dL]18/270.746
HDL-C [mg/dL]17/27<0.001
NHDL-C [mg/dL]17/270.640
ln(TG) [mg/dL]19/290.165
ln(TG/HDL)17/270.003
ln(Lip.a) [units]17/260.013
IMT-left [mm]17/260.576
IMT-right [mm]17/260.463
IMT av [mm]17/260.834
Glucose [mg/dL]19/270.882
ln(insulin+1) [μU/mL]17/270.273
C-peptide [ng/mL]16/230.656
HbA1c [%]19/280.322
QUICKI-test16/230.478
ln(proBNP) [units]16/230.905
ln(hsCRP+1) [units]17/280.440
ln(GOT) [mg/dL]18/290.499
ln(GPT) [mg/dL]18/290.098
ln(GGT) [mg/dL]18/290.048
Ezetimibe19/232 (10.5)3 (13.0)1.000
Nicotinic acid19/230 (0.0)2 (8.7)0.556
Fibrates19/232 (10.5)9 (39.1)0.081
Statins19/2311 (57.9)19 (82.6)0.155
CVD18/271 (5.6)8 (29.6)0.110
Mean steps 7 days17/210.114
Metabolic syndrome12/205 (41.7)12 (60.0)0.522
Mean treatment duration of the last taken dyslipidemic medication (days)18/280.938

-test, Chi-square test.
Data are presented as number of observations () and means ± standard deviation. BMI (body mass index), waist (waist circumference), RRS (systolic blood pressure), RRD (diastolic blood pressure), TC (total cholesterol), LDL-C (low density lipoprotein cholesterol), HDL-C (high density lipoprotein cholesterol), NHDL-C (non-high density lipoprotein cholesterol), TG (triglycerides), TG/HDL (triglyceride/HDL-cholesterol ratio), Lip.a (lipoprotein (a)), IMT (carotid intima media thickness), HbA1c (glycated hemoglobin A1c), QUICKI (quantitative insulin sensitivity check index), proBNP (pro B-type natriuretic peptide), hsCRP (high sensitive C-reactive protein), GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transaminase), GGT (gamma-glutamyl transferase), and CVD (cardiovascular disease).